Afficher la notice abrégée

dc.contributor.authorGarrido Moraga, Rocío
dc.contributor.authorSerrano Lorenzo, Pablo
dc.contributor.authorEsteban Amo, María J.
dc.contributor.authorBellusci, Marcello
dc.contributor.authorFuente García, Miguel Ángel de la 
dc.contributor.authorArenas, Joaquín
dc.contributor.authorGonzález Quintana, Adrián
dc.contributor.authorUgalde, Cristina
dc.contributor.authorSimarro Grande, María 
dc.contributor.authorMartín Casanueva, Miguel Ángel
dc.date.accessioned2026-03-24T12:44:48Z
dc.date.available2026-03-24T12:44:48Z
dc.date.issued2026
dc.identifier.citationMitochondrion, 2026, vol. 89, p. 102149es
dc.identifier.issn1567-7249es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/83787
dc.descriptionProducción Científicaes
dc.description.abstractThis study examines two rare compound heterozygous missense variants in the SDHA gene, c.1535G > A (p. R512Q) and c.1753C > T (p.R585W), identified in a pediatric patient presenting with neurological manifesta- tions, including epilepsy, developmental delay, and optic atrophy. The SDHA gene encodes a key component of succinate dehydrogenase (SDH), an essential enzyme complex at the intersection of two fundamental metabolic pathways: the Krebs cycle, and the mitochondrial respiratory chain (MRC). Patient-derived fibroblasts were used to evaluate the impact of the mutations on SDH activity and MRC as- sembly and function. The analysis revealed significant decreases in SDH activity and subunit levels, as well as impaired assembly. Additionally, complex I (CI) activity and CI-containing supercomplexes formation were also impaired, indicating more widespread mitochondrial dysfunction. Unexpectedly, basal and maximal respiration rates remained unchanged, though spare respiratory capacity was significantly reduced. These findings demonstrate the deleterious effects of the c.1535G > A and c.1753C > T variants, which had previously been associated with primary mitochondrial disorder (PMD) and tumors but had not been functionally validated until nowes
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherElsevieres
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.classificationSDHA genees
dc.subject.classificationCompound heterozygous mutationses
dc.subject.classificationMitochondrial dysfunctiones
dc.subject.classificationNeurological disorderses
dc.titleImpact of compound heterozygous SDHA variants on mitochondrial function in pediatric with neurological diseasees
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holder© 2026 The Author(s)es
dc.identifier.doi10.1016/j.mito.2026.102149es
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S1567724926000395es
dc.identifier.publicationfirstpage102149es
dc.identifier.publicationtitleMitochondriones
dc.identifier.publicationvolume89es
dc.peerreviewedSIes
dc.description.projectEsta investigación fue financiada por el Instituto de Salud Carlos III (ISCIII) y el Ministerio de Ciencia e Innovación (Madrid, España; cofinanciado por el Fondo Europeo de Desarrollo Regional «Una forma de hacer Europa»), subvención número PI21/00381es
dc.description.projectAgencia Estatal de Investigación, subvención número PID2023-150506OB-I00es
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones
dc.subject.unesco3201.02 Genética Clínicaes


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée